Health & Fitness
Health and Fitness
Health and Fitness 
Wed, January 4, 2012
Unigene to Present at Biotech Showcasea" 2012 in San Francisco on January 9
Unigene to Present at Biotech Showcasea" 2012 in San Francisco on January... -- BOONTON, N.J., Jan. 4, 2012 /PRNewswire/ --
Unigene to Present at Biotech Showcasea" 2012 in San Francisco on January 9
BOONTON, N.J., Jan. 4, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE),a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will present a corporate overview at the Biotech Showcase™ 2012 in San Francisco, CA on Monday, January 9, 2012 at 11:30 a.m. PT (2:30 p.m. ET). Mr. Palmer's presentation will include an overview of Unigene's industry-leading oral peptide delivery platform and pipeline along with the Company's business outlook and expected milestones for 2012.
A live webcast of the presentation will be available by visiting the Investors and Media section under the Events tab of the Unigene web site, [ http://www.unigene.com ]. Participants should allow approximately 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
[ jthomas@unigene.com ]
Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / June Gregg
212-827-0020
[ jrando@tiberend.com ] / [ jgregg@tiberend.com ]
SOURCE Unigene Laboratories, Inc.
[ Back to top ] RELATED LINKS
[ http://www.unigene.com ]